Posted on 24/02/2010 in Pharmaceutical Company Product News Gilead Sciences has been granted approval from the Food and Drug Administration (FDA) for its drug Cayston to be used to treat respiratory symptoms in cystic fibrosis patients.
The drug, which has also received conditional approval from European Union regulators in the last year, becomes the first inhaled anti-pseudomonal treatment to be ratified for cystic fibrosis sufferers in more than a decade.
Gilead considers the treatment to be a potentially promising therapy option for sufferers of a disease which causes respiratory and digestive ailments among around 70,000 people globally.
Dr Norbert Bischofberger, Gilead's executive vice-president of research and development and chief scientific officer, gave thanks to those involved in the clinical studies which supported the drug's approval.
He added: "We look forward to making Cayston available to the cystic fibrosis community as soon as possible."
Last week, the company published new trial data of a new oral treatment which it believes could prove an important option for sufferers of HIV.Other news stories from 24/02/2010
Read more in the Zenopa News Archive
How this news is generated
|
